首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2018年 9期 肝衰竭与人工肝 => 病毒性肝炎 =>HBV核心相关抗原对PEG-IFNα治疗..
HBV核心相关抗原对PEG-IFNα治疗HBeAg阳性慢性乙型肝炎患者效果的预测价值
Value of serum hepatitis B virus core-related antigen in predicting the treatment outcome of HBeAg-positive chronic hepatitis B patients treated with pegylated interferon-α
文章发布日期:2018年08月06日  来源:  作者:王晴,许志强,刘瑞霞,等  点击次数:435次  下载次数:59次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的评价HBV核心相关抗原(HBcrAg)对HBeAg阳性慢性乙型肝炎患者PEG-IFNα治疗效果的预测价值。方法选取2012年5月-2015年6月在徐州医科大学附属医院感染科接受PEG-IFNα治疗的HBeAg阳性慢性乙型肝炎患者79例,疗程48周,疗程结束后随访至少24周。分别检测治疗前以及治疗12周、24周、48周时HBcrAg、HBV血清标志物、HBV DNA以及ALT水平。服从正态分布的计量资料组间比较采用t检验,非正态分布的计量资料组间比较采用Mann-Whitney U检验;计数资料组间比较采用χ2或Fisher确切概率法,相关性分析采用Pearson相关分析,采用二分类logistic回归分析筛选完全应答的影响因素;采用受试者工作特征曲线判断HBcrAg对实现完全应答的预测价值。结果79例接受PEG-IFNα抗病毒治疗的HBeAg阳性慢性乙型肝炎患者治疗结束后随访24周,35例实现了完全应答。应答组相较于非应答组具有更低的基线HBsAg水平(P=0.008)、HBeAg水平(P<0.001)以及HBcrAg水平(P=0.002)。基线HBcrAg与HBV DNA (r=0.325,P=0.003)、HBsAg水平(r=0.468,P<0.001)、HBeAg水平(r=0.695,P<0.001)均呈正相关,与ALT水平无相关性。血清HBcrAg水平在治疗过程中总体呈下降趋势,应答组HBcrAg水平在治疗12周下降幅度大于非应答组(Z=-2.653,P=0.008)。治疗12周时HBcrAg水平为完全应答的独立危险因素(比值比=5510,95%可信区间:1.656~18.326,P<0.05)。血清HBcrAg的最佳截断值为6.45 log10U/ml,ROC曲线下面积为0.845。结论 PEG-IFNα抗病毒治疗前HBcrAg与HBsAg、HBeAg、HBV DNA有较好的相关性。治疗12周时血清HBcrAg水平对PEG-IFNα治疗后实现完全应答具有预测作用。
【Abstract】:ObjectiveTo investigate the value of hepatitis B virus core-related antigen (HBcrAg) in predicting the treatment outcome of HBeAg-positive chronic hepatitis B (CHB) patients treated with pegylated interferon-α (PEG-IFNα). MethodsA total of 79 HBeAg-positive CHB patients who were treated with PEG-IFNα in Department of Infectious Diseases in The Affiliated Hospital of Xuzhou Medical University from May 2012 to June 2015 were enrolled. The course of treatment was 48 weeks, and the patients were followed up for at least 24 weeks after treatment. HBcrAg, HBV serum markers, HBV DNA, and alanine aminotransferase (ALT) level were measured before treatment and at weeks 12, 24, and 48 of treatment. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test or the Fisher′s exact test was used for comparison of categorical data between groups; a Pearson correlation analysis was performed to investigate correlation; a binary logistic regression analysis was used to identify the influencing factors for complete response; the receiver operating characteristic (ROC) curve was used to investigate the value of HBcrAg in predicting complete response. ResultsAmong the 79 HBeAg-positive CHB patients who were treated with PEG-IFNα antiviral therapy and then followed up for 24 weeks, 35 achieved complete response. Compared with the non-response group, the response group had a significantly lower baseline HBsAg level (P=0.008), HBeAg level (P<0.001), and HBcrAg level (P=0.002). Baseline HBcrAg was positively correlated with HBV DNA (r=0325, P=0003), HBsAg level (r=0.468, P<0.001), and HBeAg level (r=0.695, P<0.001) and was not correlated with ALT level. Serum HBcrAg tended to decrease during treatment, and at week 12 of treatment, the response group had a significantly greater reduction in HBcrAg level compared with the non-response group (Z=-2.653, P=0.008). HBcrAg level at week 12 of treatment was an independent risk factor for complete response (odds ratio=5.510, 95% confidence interval: 1.656-18.326, P<0.05). The optimal cut-off value of serum HBcrAg was 6.45 log10U/ml, and the area under the ROC curve was 0.845. ConclusionHBcrAg is correlated with HBsAg, HBeAg, and HBV DNA before PEG-IFNα antiviral therapy. Serum HBcrAg level at week 12 of treatment can be used to predict complete response after PEG-IFNα treatment.
【关键字】:肝炎, 乙型, 慢性; 乙型肝炎核心相关抗原; 聚乙二醇干扰素-α; 治疗结果
【Key words】:hepatitis B, chronic; hepatitis B virus core-related antigen; pegylated interferon-α; treatment outcome
【引证本文】:WANG Q, XU ZQ, LIU RX, et al. Value of serum hepatitis B virus core-related antigen in predicting the treatment outcome of HBeAg-positive chronic hepatitis B patients treated with pegylated interferon-α[J]. J Clin Hepatol, 2018, 34(9): 1879-1883. (in Chinese)
王晴, 许志强, 刘瑞霞, 等. HBV核心相关抗原对PEG-IFNα治疗HBeAg阳性慢性乙型肝炎患者效果的预测价值[J]. 临床肝胆病杂志, 2018, 34(9): 1879-1883.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号